Exelixis (EXEL) Total Non-Current Liabilities (2010 - 2026)

Exelixis (EXEL) recorded quarterly Total Non-Current Liabilities of $540.5 million in Q2 2026, down 6.6% quarter-over-quarter from $578.7 million in Q1 2026, and down 7.8% on a YoY basis from $586.2 million in Q2 2025.

Exelixis (EXEL) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends

Exelixis' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $540.5 million for Q2 2026.

  • In Q2 2026, Total Non-Current Liabilities fell 7.8% year-over-year to $540.5 million; the TTM figure through Apr 2026 stood at $540.5 million (down 7.8% YoY), while the FY2026 annual figure was $578.7 million, down 2.68% from the prior year.
  • Total Non-Current Liabilities was $540.5 million for Q2 2026 at Exelixis, down from $578.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $594.6 million in Q1 2025 to a low of $347.8 million in Q2 2022.
  • Historically, Total Non-Current Liabilities has averaged $534.7 million across 5 years, with a median of $543.7 million in 2024.
  • The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities jumped 49.78% in 2023, then fell 7.8% in 2026.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $514.5 million in 2022, then rose by 13.54% to $584.2 million in 2023, then rose by 0.78% to $588.8 million in 2024, then retreated by 6.55% to $550.2 million in 2025, then retreated by 1.77% to $540.5 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $540.5 million (Q2 2026), $578.7 million (Q1 2026), and $550.2 million (Q4 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn - 42,980.09
2 Belite Bio 56,560.00 Bn 56,560.00 Bn - -
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn - 11.03 Mn
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn 95.20 Mn
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn - -
6 Evaxion A 1,536.68 Bn 1,536.67 Bn - -
7 Psyence Biomedical 238.34 Bn 238.33 Bn - 644,700.00
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn 5.87 Bn
9 Abivax 95.45 Bn 95.45 Bn - 64.76 Mn
10 Exelixis 13.71 Bn 12.93 Bn 590.86 Mn 540.52 Mn

Historic Data

Download Data
DateValue
Apr 3, 2026 540.52 Mn
Jan 2, 2026 578.68 Mn
Oct 3, 2025 550.24 Mn
Jul 4, 2025 515.95 Mn
Apr 4, 2025 586.23 Mn
Jan 3, 2025 594.59 Mn
Sep 27, 2024 588.79 Mn
Jun 28, 2024 543.72 Mn
Mar 29, 2024 574.48 Mn
Dec 29, 2023 584.22 Mn
Sep 29, 2023 567.67 Mn
Jun 30, 2023 541.04 Mn
Mar 31, 2023 520.84 Mn
Dec 30, 2022 514.53 Mn
Sep 30, 2022 468.06 Mn
Jul 1, 2022 472.75 Mn
Apr 1, 2022 347.75 Mn
Dec 31, 2021 397.60 Mn
Oct 1, 2021 331.20 Mn
Jul 2, 2021 317.13 Mn